Formulation Development
OKYO Pharma to Release New & Comprehensive Data GFrom Phase 2 Dry Eye Disease Trial
OKYO Pharma Limited recently announced it will be releasing new and comprehensive efficacy data readout from the Phase 2 trial of OK-101 in dry eye disease on….
ACELYRIN Announces Positive Phase 1/2 PoC Data for First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease
ACELYRIN, INC. recently announced positive proof-of-concept data from an ongoing Phase 1/2 trial of lonigutamab in thyroid eye disease (TED). Lonigutamab is a subcutaneously….
RespireRx Pharmaceuticals Reports Preclinical Research Demonstrating the Ability of its Lead Clinical AMPAkine to Improve Bladder Function After Spinal Cord Injury
RespireRx Pharmaceuticals Inc. recently announce that, as part of an ongoing collaboration, a scientist team led by Dr. David Fuller of the University of Florida…
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD & Stress-Induced Anxiety Therapeutic
Silo Pharma, Inc. recently announced it has exercised its option to license SPC-15, a prophylactic treatment for stress-induced affective disorders including anxiety and PTSD, from…
TFF Pharmaceuticals Announces Update on Clinical Programs
TFF Pharmaceuticals, Inc. recently announced data updates and strategic prioritization of its clinical programs. Based on positive data from the ongoing Phase 2 study of…
Petros Pharmaceuticals Successfully Launches AI Tool in Collaboration With Multi-Billion-Dollar Software Provider
Petros Pharmaceuticals, Inc. recently announced it has successfully launched its artificial intelligence (AI) tool developed as a result of its collaboration with a multi-billion-dollar software developer.…
Revive Therapeutics to Submit Type C Meeting Request With FDA for Bucillamine to Treat Long COVID
Revive Therapeutics Ltd. recently announced the FDA advised the company to submit a Type C meeting request to discuss evaluating a proposed Phase 2 clinical…
Hovione & GEA Strengthen Partnership to Advance Continuous Tableting Technology
Hovione and GEA recently announced the next stage of their partnership, with new development agreements, the launch of the ConsiGma CDC flex as well as…
WHITEPAPER - Manufacturing of 10-mg Loratadine Self-Emulsifying Drug Delivery System (SEDDS) Tablets by Direct Compression With ABISORB-DC & ABISOL Emulsion Preconcentrate Kit
10-mg loratadine SEDDS were successfully manufactured with ABISORB-DC(TM) and ABISOL(TM) 2 by direct compression on a rotary tablet press, employing standard pharmaceutical manufacturing equipment…..
ReciBioPharm & GeneVentiv Therapeutics Partner to Advance First AAV-Based Gene Therapy for Haemophilia Patients With Inhibitors
ReciBioPharm has recently announced a collaboration agreement with GeneVentiv Therapeutics to advance development of an Adeno-Associated Virus (AAV)-based universal gene therapy for….
Anavex Life Sciences Initiates Placebo-Controlled US Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
Anavex Life Sciences Corp. recently announced the first patient in its US FDA cleared placebo-controlled Phase 2 clinical study of ANAVEX3-71 for the treatment of…
BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine
BioXcel Therapeutics, Inc. recently reported the European Patent Office (EPO) granted the company’s European Patent No. 3,562,486 on March 13, 2024. The 486 patent covers…
Curia Appoints Steve Lavezoli as Vice President, Biologics
Curia, a leading contract research, development and manufacturing organization, recently announced it has appointed Steve Lavezoli as Vice President of Biologics effective Feb. 26. Lavezoli…
Atrogi Announces Positive Clinical Data From First-in-Class Insulin-Independent Treatment for Type 2 Diabetes
Atrogi recently announced the full set of results from its Phase 1 a/b trial with ATR-258, its first-in-class treatment for type 2 diabetes (T2D). This…
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
Cleavable capping technology confines therapeutic activity to the local tumor micro environment which increases the anticipated therapeutic window in patients….
Noramco Announces Strategic Alignment With Purisys & Halo Pharma, Launching the Noramco Group as an Integrated North American-Based API & Drug Product Supply Chain Services Provider
Noramco recently announced its launch of the Noramco Group, a newly created comprehensive North American-based supply chain solution including subsidiaries Purisys, Noramco, and the newly acquired….
Lirum Therapeutics Announces Positive Data on LX-101, a Novel Clinical-Stage Targeted Therapy Demonstrating Potent Preclinical Activity Against IGF-Related Cancers
Lirum Therapeutics, Inc. recently announced the acceptance for presentation of positive data on LX-101, a novel clinical-stage targeted therapy directed to the insulin-like growth factor…
GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T Cell Modulators
GRI Bio, Inc. recently announced the Canadian Intellectual Property Office (CIPO) has issued a notice of allowance for Patent Application No. 3,007,970 titled, Prevention and…
SciSparc Achieves Major Milestone With First Patient Dosed in Autism Spectrum Disorder Clinical Trial
SciSparc Ltd. recently announced it has successfully dosed the first patient in its SCI-210 clinical trial at the Soroka Medical Center for pediatric patients who…
Almirall & Eloxx Pharmaceuticals Enter Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases
Almirall, S.A. and Eloxx Pharmaceuticals, Inc. recently announced the companies have entered into an exclusive license agreement for the asset ZKN-013. Under the agreement, Almirall…
